A senior executive confirmed the pharmaceutical giant is changing its pricing approach for all new drug launches in the U.S. to adapt to the Trump administration's policy aimed at lowering prescription costs.
Investors are preparing for the most concentrated week of the Q2 earnings season, with reports due from tech giants like Apple and Microsoft, alongside a key Federal Reserve interest rate decision.
Shares of MapLight Therapeutics (NASDAQ:MPLT) fell sharply after the company's Phase 2 trial for its schizophrenia drug, ML-007C-MA, showed that a once-daily dose failed to meet its primary endpoint, overshadowing the success of a twice-daily regimen.
Apnimed has filed for an initial public offering on the Nasdaq, aiming to sell 10 million shares at a price range of $14 to $16 each. The offering could raise up to $160 million for the company.
Shares of specialized cloud providers CoreWeave and Nebius climbed after a report that Nvidia is in discussions to provide a $250 billion financing guarantee for a massive OpenAI data center project, signaling continued heavy investment in AI infrastructure.
Shares of D-Wave Quantum Inc. (QBTS) jumped after the company announced an expanded agreement with AT&T, which will use its quantum computing technology to optimize complex network operations.
Analysts at Piper Sandler have upgraded Rivian and Mobileye to "overweight," citing their vertically integrated models, while downgrading Stellantis due to rising competition from Chinese automakers.
HSBC announced plans to hire over 100 artificial intelligence specialists and 100 wealth managers in Singapore, signaling a significant investment in technology and its core Asian wealth management business.
The all-cash deal values Forte Biosciences at $77 per share, a significant premium driven by the potential of its lead antibody program, FB102, for treating autoimmune diseases like vitiligo.
